DexCom, Inc. (Nasdaq: DXCM), a leading player in diabetes management technology, delivered an impressive performance in the third quarter of 2023, reporting adjusted earnings per share (EPS) of $0.50. This surpassed the consensus EPS estimate of $0.34, and the company's quarterly revenue of $975.0 million exceeded analysts' expectations of $939.24 million.

DexCom is showing confidence in its future as it increases its full-year fiscal 2023 revenue guidance. The new range is approximately $3.575 billion to $3.600 billion, in contrast to the consensus estimate of $3.54 billion for the period.

$DXCM was trading at $94.90 in after-hours, experiencing a significant boost of $13.81 (+17.03%).

In other notable news, Intel Corporation (Nasdaq: INTC), a prominent name in the tech industry, also reported strong results for the third quarter of 2023. The company's adjusted earnings of $0.41 per share outperformed the consensus EPS estimate of $0.22, and its quarterly revenue reached $14.2 billion, surpassing analysts' forecasts of $13.532 billion.

Intel is projecting a positive outlook for the fourth quarter of 2023, with expected revenue ranging from $14.6 billion to $15.6 billion and an adjusted EPS of $0.44. This differs from the consensus EPS estimate of $0.30 on revenue of $13.53 billion for the period.

$INTC was trading at $35.01, up by $2.49 (+7.66%) in after-hours.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)